Home › Funds › Vivo Capital, LLC › KTTA

Vivo Capital, LLC position in KTTA

Pasithea Therapeutics Corp · Health Care

Vivo Capital, LLC reported holding 372,796 shares of KTTA (Pasithea Therapeutics Corp) in its Q3 2026 13F filing — a position valued at US$184K, representing 0.02% of its reported portfolio and ranking #47 among its reported holdings. Vivo Capital, LLC has disclosed KTTA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)372.80K sh
Reported value held$183.79K
Portfolio Weight0.02%
First reportedQ4 2025
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Vivo Capital, LLC's KTTA position evolved

Vivo Capital, LLC first disclosed a stake in KTTA in Q4 2025 at 2,100,000 shares (US$2.7M). Across 4 filings, Vivo Capital, LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 372,796 shares valued at US$184K — a reduction of -92,675 shares quarter over quarter.. Notable position changes include a 78% trim in Q2 2026 (shares fell 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 2.10M $2.71M New
Q1 2026 2.10M $1.56M Hold
Q2 2026 465.47K $239.90K Reduce
Q3 2026 372.80K $183.79K Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KTTA and 13F data

KTTA (Pasithea Therapeutics Corp) is a Health Care company. 28 other funds we track also report a position in KTTA — the largest reported positions include Stonepine Capital Management, LLC (US$1.1M), Squadron Capital Management LLC (US$515K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KTTA

All KTTA fund holders →

FAQ

How long has Vivo Capital, LLC held KTTA?

Vivo Capital, LLC has disclosed KTTA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Vivo Capital, LLC's current position in KTTA?

As of Q3 2026, Vivo Capital, LLC holds 372.80K shares of KTTA (Pasithea Therapeutics Corp), valued at $183.79K, representing 0.02% of its reported portfolio and ranking #47.

Has Vivo Capital, LLC been buying or selling KTTA?

In the latest 13F filing (Q3 2026), Vivo Capital, LLC reduced its position in KTTA.

Which other funds hold KTTA?

Other major institutional holders of KTTA include Stonepine Capital Management, LLC, Squadron Capital Management LLC, among 28 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.